Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance

Justin M. Balko, Rebecca S. Cook, David B. Vaught, María G. Kuba, Todd W. Miller, Neil E. Bhola, Melinda E. Sanders, Nara M. Granja-Ingram, J. Joshua Smith, Ingrid M. Meszoely, Janine Salter, Mitch Dowsett, Katherine Stemke-Hale, Ana M. González-Angulo, Gordon B. Mills, Joseph A. Pinto, Henry L. Gómez, Carlos L. Arteaga

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Neoadjuvant chemotherapy (NAC) induces a pathological complete response (pCR) in ∼30% of patients with breast cancer. However, many patients have residual cancer after chemotherapy, which correlates with a higher risk of metastatic recurrence and poorer outcome than those who achieve a pCR. We hypothesized that molecular profiling of tumors after NAC would identify genes associated with drug resistance. Digital transcript counting was used to profile surgically resected breast cancers after NAC. Low concentrations of dual specificity protein phosphatase 4 (DUSP4), an ERK phosphatase, correlated with high post-NAC tumor cell proliferation and with basal-like breast cancer (BLBC) status. BLBC had higher DUSP4 promoter methylation and gene expression patterns of Ras-ERK pathway activation relative to other breast cancer subtypes. DUSP4 overexpression increased chemotherapy-induced apoptosis, whereas DUSP4 depletion dampened the response to chemotherapy. Reduced DUSP4 expression in primary tumors after NAC was associated with treatment-refractory high Ki-67 scores and shorter recurrence-free survival. Finally, inhibition of mitogen-activated protein kinase kinase (MEK) synergized with docetaxel treatment in BLBC xenografts. Thus, DUSP4 downregulation activates the Ras-ERK pathway in BLBC, resulting in an attenuated response to anti-cancer chemotherapy.

Original languageEnglish (US)
Pages (from-to)1052-1059
Number of pages8
JournalNature Medicine
Volume18
Issue number7
DOIs
StatePublished - Jul 1 2012

Fingerprint

Dual-Specificity Phosphatases
Chemotherapy
Residual Neoplasm
Drug Resistance
Breast Neoplasms
Drug Therapy
Pharmaceutical Preparations
Tumors
MAP Kinase Signaling System
Mitogen-Activated Protein Kinase Kinases
docetaxel
Neoplasms
protein phosphatase 4
Recurrence
Methylation
Cell proliferation
Phosphoric Monoester Hydrolases
Heterografts
Gene expression
Refractory materials

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. / Balko, Justin M.; Cook, Rebecca S.; Vaught, David B.; Kuba, María G.; Miller, Todd W.; Bhola, Neil E.; Sanders, Melinda E.; Granja-Ingram, Nara M.; Joshua Smith, J.; Meszoely, Ingrid M.; Salter, Janine; Dowsett, Mitch; Stemke-Hale, Katherine; González-Angulo, Ana M.; Mills, Gordon B.; Pinto, Joseph A.; Gómez, Henry L.; Arteaga, Carlos L.

In: Nature Medicine, Vol. 18, No. 7, 01.07.2012, p. 1052-1059.

Research output: Contribution to journalArticle

Balko, JM, Cook, RS, Vaught, DB, Kuba, MG, Miller, TW, Bhola, NE, Sanders, ME, Granja-Ingram, NM, Joshua Smith, J, Meszoely, IM, Salter, J, Dowsett, M, Stemke-Hale, K, González-Angulo, AM, Mills, GB, Pinto, JA, Gómez, HL & Arteaga, CL 2012, 'Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance', Nature Medicine, vol. 18, no. 7, pp. 1052-1059. https://doi.org/10.1038/nm.2795
Balko, Justin M. ; Cook, Rebecca S. ; Vaught, David B. ; Kuba, María G. ; Miller, Todd W. ; Bhola, Neil E. ; Sanders, Melinda E. ; Granja-Ingram, Nara M. ; Joshua Smith, J. ; Meszoely, Ingrid M. ; Salter, Janine ; Dowsett, Mitch ; Stemke-Hale, Katherine ; González-Angulo, Ana M. ; Mills, Gordon B. ; Pinto, Joseph A. ; Gómez, Henry L. ; Arteaga, Carlos L. / Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. In: Nature Medicine. 2012 ; Vol. 18, No. 7. pp. 1052-1059.
@article{358fd20e9a244a518b56eb0e7ca41362,
title = "Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance",
abstract = "Neoadjuvant chemotherapy (NAC) induces a pathological complete response (pCR) in ∼30{\%} of patients with breast cancer. However, many patients have residual cancer after chemotherapy, which correlates with a higher risk of metastatic recurrence and poorer outcome than those who achieve a pCR. We hypothesized that molecular profiling of tumors after NAC would identify genes associated with drug resistance. Digital transcript counting was used to profile surgically resected breast cancers after NAC. Low concentrations of dual specificity protein phosphatase 4 (DUSP4), an ERK phosphatase, correlated with high post-NAC tumor cell proliferation and with basal-like breast cancer (BLBC) status. BLBC had higher DUSP4 promoter methylation and gene expression patterns of Ras-ERK pathway activation relative to other breast cancer subtypes. DUSP4 overexpression increased chemotherapy-induced apoptosis, whereas DUSP4 depletion dampened the response to chemotherapy. Reduced DUSP4 expression in primary tumors after NAC was associated with treatment-refractory high Ki-67 scores and shorter recurrence-free survival. Finally, inhibition of mitogen-activated protein kinase kinase (MEK) synergized with docetaxel treatment in BLBC xenografts. Thus, DUSP4 downregulation activates the Ras-ERK pathway in BLBC, resulting in an attenuated response to anti-cancer chemotherapy.",
author = "Balko, {Justin M.} and Cook, {Rebecca S.} and Vaught, {David B.} and Kuba, {Mar{\'i}a G.} and Miller, {Todd W.} and Bhola, {Neil E.} and Sanders, {Melinda E.} and Granja-Ingram, {Nara M.} and {Joshua Smith}, J. and Meszoely, {Ingrid M.} and Janine Salter and Mitch Dowsett and Katherine Stemke-Hale and Gonz{\'a}lez-Angulo, {Ana M.} and Mills, {Gordon B.} and Pinto, {Joseph A.} and G{\'o}mez, {Henry L.} and Arteaga, {Carlos L.}",
year = "2012",
month = "7",
day = "1",
doi = "10.1038/nm.2795",
language = "English (US)",
volume = "18",
pages = "1052--1059",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance

AU - Balko, Justin M.

AU - Cook, Rebecca S.

AU - Vaught, David B.

AU - Kuba, María G.

AU - Miller, Todd W.

AU - Bhola, Neil E.

AU - Sanders, Melinda E.

AU - Granja-Ingram, Nara M.

AU - Joshua Smith, J.

AU - Meszoely, Ingrid M.

AU - Salter, Janine

AU - Dowsett, Mitch

AU - Stemke-Hale, Katherine

AU - González-Angulo, Ana M.

AU - Mills, Gordon B.

AU - Pinto, Joseph A.

AU - Gómez, Henry L.

AU - Arteaga, Carlos L.

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Neoadjuvant chemotherapy (NAC) induces a pathological complete response (pCR) in ∼30% of patients with breast cancer. However, many patients have residual cancer after chemotherapy, which correlates with a higher risk of metastatic recurrence and poorer outcome than those who achieve a pCR. We hypothesized that molecular profiling of tumors after NAC would identify genes associated with drug resistance. Digital transcript counting was used to profile surgically resected breast cancers after NAC. Low concentrations of dual specificity protein phosphatase 4 (DUSP4), an ERK phosphatase, correlated with high post-NAC tumor cell proliferation and with basal-like breast cancer (BLBC) status. BLBC had higher DUSP4 promoter methylation and gene expression patterns of Ras-ERK pathway activation relative to other breast cancer subtypes. DUSP4 overexpression increased chemotherapy-induced apoptosis, whereas DUSP4 depletion dampened the response to chemotherapy. Reduced DUSP4 expression in primary tumors after NAC was associated with treatment-refractory high Ki-67 scores and shorter recurrence-free survival. Finally, inhibition of mitogen-activated protein kinase kinase (MEK) synergized with docetaxel treatment in BLBC xenografts. Thus, DUSP4 downregulation activates the Ras-ERK pathway in BLBC, resulting in an attenuated response to anti-cancer chemotherapy.

AB - Neoadjuvant chemotherapy (NAC) induces a pathological complete response (pCR) in ∼30% of patients with breast cancer. However, many patients have residual cancer after chemotherapy, which correlates with a higher risk of metastatic recurrence and poorer outcome than those who achieve a pCR. We hypothesized that molecular profiling of tumors after NAC would identify genes associated with drug resistance. Digital transcript counting was used to profile surgically resected breast cancers after NAC. Low concentrations of dual specificity protein phosphatase 4 (DUSP4), an ERK phosphatase, correlated with high post-NAC tumor cell proliferation and with basal-like breast cancer (BLBC) status. BLBC had higher DUSP4 promoter methylation and gene expression patterns of Ras-ERK pathway activation relative to other breast cancer subtypes. DUSP4 overexpression increased chemotherapy-induced apoptosis, whereas DUSP4 depletion dampened the response to chemotherapy. Reduced DUSP4 expression in primary tumors after NAC was associated with treatment-refractory high Ki-67 scores and shorter recurrence-free survival. Finally, inhibition of mitogen-activated protein kinase kinase (MEK) synergized with docetaxel treatment in BLBC xenografts. Thus, DUSP4 downregulation activates the Ras-ERK pathway in BLBC, resulting in an attenuated response to anti-cancer chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84863726932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863726932&partnerID=8YFLogxK

U2 - 10.1038/nm.2795

DO - 10.1038/nm.2795

M3 - Article

C2 - 22683778

AN - SCOPUS:84863726932

VL - 18

SP - 1052

EP - 1059

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 7

ER -